Fritz Agnes-Sophie, Trendelenburg Marten, Mutke Markus
Department of Internal Medicine, University Hospital of Basel, Basel, Switzerland.
Eur J Case Rep Intern Med. 2025 Aug 18;12(9):005460. doi: 10.12890/2025_005460. eCollection 2025.
Piperacillin/tazobactam (PTZ) is known to cause cytopenia but case reports on PTZ causing combined haemolytic anaemia and thrombocytopenia are scarce. We report on a 56-year-old male who developed severe, immune-mediated thrombocytopenia and anaemia during two treatment episodes with PTZ. After the first exposure, his blood count rapidly returned to normal after discontinuation of PTZ. One year later, in the context of an unintentional re-challenge with PTZ, the level of red blood cells and platelets dropped again causing acute haemolytic anaemia and immune thrombocytopenia. Recovery was delayed after discontinuation of PTZ. PTZ should be considered as a potential cause of immune-mediated bicytopenia.
Piperacillin/tazobactam can induce immune-mediated haemolytic anaemia and thrombocytopenia.Patients with underlying alteration of the immune system might be at higher risk for bicytopenia.
已知哌拉西林/他唑巴坦（PTZ）可导致血细胞减少，但关于PTZ引起溶血性贫血和血小板减少合并症的病例报告很少。我们报告了一名56岁男性，他在两次接受PTZ治疗期间出现了严重的、免疫介导的血小板减少和贫血。首次接触后，停用PTZ后他的血细胞计数迅速恢复正常。一年后，在无意中再次使用PTZ的情况下，红细胞和血小板水平再次下降，导致急性溶血性贫血和免疫性血小板减少。停用PTZ后恢复延迟。PTZ应被视为免疫介导的双血细胞减少的潜在原因。
哌拉西林/他唑巴坦可诱发免疫介导的溶血性贫血和血小板减少。免疫系统存在潜在改变的患者可能发生双血细胞减少的风险更高。
